Logo image of KALA

KALA BIO INC (KALA) Stock Fundamental Analysis

USA - NASDAQ:KALA - US4831192020 - Common Stock

0.765 USD
-0.03 (-4.22%)
Last: 10/30/2025, 3:26:49 PM
Fundamental Rating

1

Overall KALA gets a fundamental rating of 1 out of 10. We evaluated KALA against 534 industry peers in the Biotechnology industry. KALA has a bad profitability rating. Also its financial health evaluation is rather negative. KALA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

KALA had negative earnings in the past year.
In the past year KALA has reported a negative cash flow from operations.
KALA had negative earnings in each of the past 5 years.
In the past 5 years KALA always reported negative operating cash flow.
KALA Yearly Net Income VS EBIT VS OCF VS FCFKALA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

The Return On Assets of KALA (-73.89%) is worse than 64.04% of its industry peers.
Looking at the Return On Equity, with a value of -624.60%, KALA is doing worse than 79.40% of the companies in the same industry.
Industry RankSector Rank
ROA -73.89%
ROE -624.6%
ROIC N/A
ROA(3y)-65.78%
ROA(5y)-69.35%
ROE(3y)-371.5%
ROE(5y)-413.54%
ROIC(3y)N/A
ROIC(5y)N/A
KALA Yearly ROA, ROE, ROICKALA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400 -600 -800

1.3 Margins

KALA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KALA Yearly Profit, Operating, Gross MarginsKALA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for KALA has been increased compared to 1 year ago.
KALA has more shares outstanding than it did 5 years ago.
KALA has a better debt/assets ratio than last year.
KALA Yearly Shares OutstandingKALA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
KALA Yearly Total Debt VS Total AssetsKALA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -21.71, we must say that KALA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -21.71, KALA is doing worse than 85.96% of the companies in the same industry.
A Debt/Equity ratio of 2.65 is on the high side and indicates that KALA has dependencies on debt financing.
The Debt to Equity ratio of KALA (2.65) is worse than 80.52% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.65
Debt/FCF N/A
Altman-Z -21.71
ROIC/WACCN/A
WACCN/A
KALA Yearly LT Debt VS Equity VS FCFKALA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

2.3 Liquidity

KALA has a Current Ratio of 1.99. This is a normal value and indicates that KALA is financially healthy and should not expect problems in meeting its short term obligations.
KALA has a worse Current ratio (1.99) than 75.28% of its industry peers.
A Quick Ratio of 1.99 indicates that KALA should not have too much problems paying its short term obligations.
KALA has a Quick ratio of 1.99. This is in the lower half of the industry: KALA underperforms 73.22% of its industry peers.
Industry RankSector Rank
Current Ratio 1.99
Quick Ratio 1.99
KALA Yearly Current Assets VS Current LiabilitesKALA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

KALA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.29%, which is quite impressive.
EPS 1Y (TTM)51.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

KALA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.87% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y52.86%
EPS Next 2Y31.9%
EPS Next 3Y23.87%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KALA Yearly Revenue VS EstimatesKALA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2019 2020 2021 2022 2029 2030 2031 2032 50M 100M 150M
KALA Yearly EPS VS EstimatesKALA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -50 -100

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KALA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KALA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KALA Price Earnings VS Forward Price EarningsKALA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KALA Per share dataKALA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

KALA's earnings are expected to grow with 23.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.9%
EPS Next 3Y23.87%

More info and screens

0

5. Dividend

5.1 Amount

KALA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KALA BIO INC

NASDAQ:KALA (10/30/2025, 3:26:49 PM)

0.765

-0.03 (-4.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2025-08-08/bmo
Earnings (Next)11-17 2025-11-17/amc
Inst Owners54.68%
Inst Owner Change0%
Ins Owners2.67%
Ins Owner Change-10.18%
Market Cap5.37M
Revenue(TTM)N/A
Net Income(TTM)-35652000
Analysts82
Price Target31.37 (4000.65%)
Short Float %14.79%
Short Ratio0.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.54%
Min EPS beat(2)25.18%
Max EPS beat(2)31.9%
EPS beat(4)4
Avg EPS beat(4)27.22%
Min EPS beat(4)22.13%
Max EPS beat(4)31.9%
EPS beat(8)5
Avg EPS beat(8)-1.08%
EPS beat(12)7
Avg EPS beat(12)-4.59%
EPS beat(16)8
Avg EPS beat(16)-10.91%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)23%
PT rev (3m)136.54%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.42%
EPS NY rev (3m)9.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.94
P/tB 0.94
EV/EBITDA N/A
EPS(TTM)-6.79
EYN/A
EPS(NY)-2.87
Fwd EYN/A
FCF(TTM)-3.9
FCFYN/A
OCF(TTM)-3.88
OCFYN/A
SpS0
BVpS0.81
TBVpS0.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -73.89%
ROE -624.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.78%
ROA(5y)-69.35%
ROE(3y)-371.5%
ROE(5y)-413.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 2.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.99
Quick Ratio 1.99
Altman-Z -21.71
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)113.01%
Cap/Depr(5y)128.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.89%
EPS Next Y52.86%
EPS Next 2Y31.9%
EPS Next 3Y23.87%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y0.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y57.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y57.82%
OCF growth 3YN/A
OCF growth 5YN/A

KALA BIO INC / KALA FAQ

What is the fundamental rating for KALA stock?

ChartMill assigns a fundamental rating of 1 / 10 to KALA.


Can you provide the valuation status for KALA BIO INC?

ChartMill assigns a valuation rating of 1 / 10 to KALA BIO INC (KALA). This can be considered as Overvalued.


How profitable is KALA BIO INC (KALA) stock?

KALA BIO INC (KALA) has a profitability rating of 0 / 10.


What is the earnings growth outlook for KALA BIO INC?

The Earnings per Share (EPS) of KALA BIO INC (KALA) is expected to grow by 52.86% in the next year.